Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition.
Cell Mol Gastroenterol Hepatol
; 3(3): 447-468, 2017 May.
Article
em En
| MEDLINE
| ID: mdl-28462383
BACKGROUND & AIMS: Total parenteral nutrition (TPN), a crucial treatment for patients who cannot receive enteral nutrition, is associated with mucosal atrophy, barrier dysfunction, and infectious complications. Glucagon-like peptide-2 (GLP-2) and epidermal growth factor (EGF) improve intestinal epithelial cell (IEC) responses and attenuate mucosal atrophy in several TPN models. However, it remains unclear whether these 2 factors use distinct or overlapping signaling pathways to improve IEC responses. We investigated the interaction of GLP-2 and EGF signaling in a mouse TPN model and in patients deprived of enteral nutrition. METHODS: Adult C57BL/6J, IEC-Egfrknock out (KO) and IEC-pik3r1KO mice receiving TPN or enteral nutrition were treated with EGF or GLP-2 alone or in combination with reciprocal receptor inhibitors, GLP-2(3-33) or gefitinib. Jejunum was collected and mucosal atrophy and IEC responses were assessed by histologic, gene, and protein expression analyses. In patients undergoing planned looped ileostomies, fed and unfed ileum was analyzed. RESULTS: Enteral nutrient deprivation reduced endogenous EGF and GLP-2 signaling in mice and human beings. In the mouse TPN model, exogenous EGF or GLP-2 attenuated mucosal atrophy and restored IEC proliferation. The beneficial effects of EGF and GLP-2 were decreased upon Gefitinib treatment and in TPN-treated IEC-EgfrKO mice, showing epidermal growth factor-receptor dependency for these IEC responses. By contrast, in TPN-treated IEC-pi3kr1KO mice, the beneficial actions of EGF were lost, although GLP-2 still attenuated mucosal atrophy. CONCLUSIONS: Upon enteral nutrient deprivation, exogenous GLP-2 and EGF show strong interdependency for improving IEC responses. Understanding the differential requirements for phosphatidylinositol 3-kinase/phosphoAKT (Ser473) signaling may help improve future therapies to prevent mucosal atrophy.
EGF; EGF, epidermal growth factor; EGFR; EGFR, epidermal growth factor receptor; GLP-2; GLP-2 (3-33), glucagon-like peptide 2 antagonist; GLP-2, glucagon-like peptide 2; GLP2R, glucagon-like peptide 2 receptor; IEC, intestinal epithelial cell; IGF-1, insulin-like growth factor 1; ISC, intestinal stem cell; IV, intravenous; KO, knock out; Lgr5, leucine-rich repeat-containing G-proteincoupled receptor 5; Mucosal Atrophy; PCNA, proliferating cell nuclear antigen; PCR, polymerase chain reaction; PI3K; PI3K, phosphatidylinositol 3-kinase; PI3KR1, phosphatidylinositol 3-kinase p85a; SBS, short-bowel syndrome; TNF, tumor necrosis factor; TPN, total parenteral nutrition; TUNEL, terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick-end labeling; Total Parenteral Nutrition; WT, wild-type; bp, base pair; mRNA, messenger RNA
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article